Comparison of hepatic resection and systemic treatment of breast cancer liver metastases: A propensity score matching study
Comparison of hepatic resection and systemic treatment of breast cancer liver metastases: A propensity score matching study
复制标题
乳腺癌肝转移肝切除与全身治疗的比较：倾向评分匹配研究
DOI：
10.1016/j.amjsurg.2020.02.047
复制
发表时间：
2020-10-01
影响因子：
3
通讯作者：
Wang, Lu
中科院分区：
文献类型：
--
作者：
Feng, Yun;He, Xi-Gan;Wang, Lu
背景：手术在乳腺癌肝转移（BCLM）中的作用仍然难以捉摸，目前的应用有限。我们的目的是研究与非肝切除（NHR）治疗相比，BCLM的肝切除（HR）是否能改善生存率。方法：将2008年至2018年的384例BCLM患者分为两组。结果：经PSM后，HR组平均总生存期（OS）为61.8个月，1、3、5年OS率分别为92.6%，54.7%和54.7%; NHR组分别为38.6个月、79.2%、45.6%和21.9%（P < 0.007）。多因素分析表明激素受体状态（p = 0.039）和肝切除术（p = 0.032）是独立的预后factor.Conclusion：我们的研究表明，肝切除术产生的生存效益安全的药物治疗相比，尤其是对患者的激素受体阳性。(C)2020爱思唯尔公司All rights reserved.
Background: The role of surgery in breast cancer liver metastases (BCLM) remains elusive, and current application is limited. Our aim is to investigate whether hepatic resection (HR) of BCLM improves survival compared with non-hepatic resection (NHR) treatment.Methods: Three hundred and eighty-four patients with BCLM from 2008 to 2018 were divided into two groups. Propensity score matching (PSM) analysis was used to compare the clinical outcomes.Results: After PSM the mean overall survival (OS) and the 1, 3, and 5-year OS rates in HR group were 61.8 months, 92.6%, 54.7% and 54.7%, respectively; while for NHR group these values were 38.6 months, 79.2%, 45.6% and 21.9%, respectively (p < 0.007). Multivariate analysis indicated hormonal receptor status (p = 0.039) and hepatic resection (p = 0.032) were independent prognostic factors.Conclusion: Our study revealed that hepatectomy yields a survival benefit safely compared with medical treatments, especially for patients with positive hormonal receptors. (C) 2020 Elsevier Inc. All rights reserved.